Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings

Drug and Alcohol Dependence

Volumn 129, Issue 3, 2013, Pages 167-179

  Panenka, William J ^a   Procyshyn, Ric M ^a,b   Lecomte, Tania ^c   MacEwan, G William ^a   Flynn, Sean W ^a   Honer, William G ^a,b   Barr, Alasdair M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Mental Health and Addictions Research Institute   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Addiction; Cognitive impairment; Drugs of abuse; Methamphetamine; Neurotoxicity; Psychostimulant

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BACLOFEN; DEXAMPHETAMINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; METHADONE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; NEUROLEPTIC AGENT; NICOTINE; ONDANSETRON; PAROXETINE; PLACEBO; RISPERIDONE; SERTRALINE; VIGABATRIN;

BEHAVIOR THERAPY; BRAIN REGION; CLINICAL EFFECTIVENESS; CLINICAL STUDY; COCAINE DEPENDENCE; COGNITIVE DEFECT; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; HUMAN; LOW DRUG DOSE; MENTAL PERFORMANCE; METHAMPHETAMINE DEPENDENCE; MOLECULAR DYNAMICS; NEUROTOXICITY; NONHUMAN; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOPHYSIOLOGY; PSYCHOSIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; COGNITION DISORDERS; DRUG EVALUATION, PRECLINICAL; HUMANS; METHAMPHETAMINE;

EID: 84876093245     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.11.016     Document Type: Review

References (211)

1. Adams D.H., Hanson G.R., Keefe K.A. Cocaine and methamphetamine differentially affect opioid peptide mRNA expression in the striatum. J. Neurochem. 2000, 75:2061-2070.
2. Adams D.H., Hanson G.R., Keefe K.A. Distinct effects of methamphetamine and cocaine on preprodynorphin messenger RNA in rat striatal patch and matrix. J. Neurochem. 2003, 84:87-93.
3. Alburges M.E., Keefe K.A., Hanson G.R. Unique responses of limbic met-enkephalin systems to low and high doses of methamphetamine. Brain Res. 2001, 905:120-126.
4. Alicata D., Chang L., Cloak C., Abe K., Ernst T. Higher diffusion in striatum and lower fractional anisotropy in white matter of methamphetamine users. Psychiatry Res. 2009, 174:1-8.
5. Anglin M.D., Burke C., Perrochet B., Stamper E., Dawud-Noursi S. History of the methamphetamine problem. J. Psychoactive Drugs 2000, 32:137-141.
6. Armstrong B.D., Noguchi K.K. The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats. Neurotoxicology 2004, 25:905-914.
7. Barr A.M., Markou A. Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci. Biobehav. Rev. 2005, 29:675-706.
8. Barr A.M., Phillips A.G. Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement. Psychopharmacology (Berl.) 1999, 141:99-106.
9. Barr A.M., Phillips A.G. Increased successive negative contrast in rats withdrawn from an escalating-dose schedule of d-amphetamine. Pharmacol. Biochem. Behav. 2002, 71:293-299.
10. Barr A.M., Fiorino D.F., Phillips A.G. Effects of withdrawal from an escalating dose schedule of d-amphetamine on sexual behavior in the male rat. Pharmacol. Biochem. Behav. 1999, 64:597-604.
11. Barr A.M., Brotto L.A., Phillips A.G. Chronic corticosterone enhances the rewarding effect of hypothalamic self-stimulation in rats. Brain Res. 2000, 875:196-201.
12. Barr A.M., Hofmann C.E., Weinberg J., Phillips A.G. Exposure to repeated, intermittent d-amphetamine induces sensitization of HPA axis to a subsequent stressor. Neuropsychopharmacology 2002, 26:286-294.
13. Barr A.M., Markou A., Phillips A.G. A 'crash' course on psychostimulant withdrawal as a model of depression. Trends Pharmacol. Sci. 2002, 23:475-482.
14. Barr A.M., Zis A.P., Phillips A.G. Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats. Psychopharmacology (Berl.) 2002, 159:196-202.
15. Barr A.M., Panenka W.J., Macewan G.W., Thornton A.E., Lang D.J., Honer W.G., Lecomte T. The need for speed: an update on methamphetamine addiction. J. Psychiatry Neurosci. 2006, 31:301-313.
16. Belcher A.M., O'Dell S.J., Marshall J.F. Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity. Neuropsychopharmacology 2005, 30:2026-2035.
17. Berman S., O'Neill J., Fears S., Bartzokis G., London E.D. Abuse of amphetamines and structural abnormalities in the brain. Ann. N. Y. Acad. Sci. 2008, 1141:195-220.
18. Boileau I., Rusjan P., Houle S., Wilkins D., Tong J., Selby P., Guttman M., Saint-Cyr J.A., Wilson A.A., Kish S.J. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker?. J. Neurosci. 2008, 28:9850-9856.
19. Boyda H.N., Tse L., Procyshyn R.M., Honer W.G., Barr A.M. Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol. Sci. 2010, 31:484-497.
20. Brodie J.D., Figueroa E., Laska E.M., Dewey S.L. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005, 55:122-125.
21. Brown J.M., Hanson G.R., Fleckenstein A.E. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J. Pharmacol. Exp. Ther. 2001, 296:762-767.
22. Bruijnzeel A.W., Bishnoi M., van Tuijl I.A., Keijzers K.F., Yavarovich K.R., Pasek T.M., Ford J., Alexander J.C., Yamada H. Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats. Psychopharmacology (Berl.) 2010, 212:485-499.
23. Bunzow J.R., Sonders M.S., Arttamangkul S., Harrison L.M., Zhang G., Quigley D.I., Darland T., Suchland K.L., Pasumamula S., Kennedy J.L., Olson S.B., Magenis R.E., Amara S.G., Grandy D.K. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 2001, 60:1181-1188.
24. Cadet J.L., Krasnova I.N. Molecular bases of methamphetamine-induced neurodegeneration. Int. Rev. Neurobiol. 2009, 88:101-119.
25. Callaghan R.C., Cunningham J.K., Sajeev G., Kish S.J. Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov. Disord. 2010, 25:2333-2339.
26. Callaghan R.C., Cunningham J.K., Sykes J., Kish S.J. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend. 2012, 120:35-40.
27. Castel M.N., Morino P., Nylander I., Terenius L., Hokfelt T. Differential dopaminergic regulation of the neurotensin striatonigral and striatopallidal pathways in the rat. Eur. J. Pharmacol. 1994, 262:1-10.
28. Chang L., Ernst T., Speck O., Patel H., DeSilva M., Leonido-Yee M., Miller E.N. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res. 2002, 114:65-79.
29. Chang L., Cloak C., Patterson K., Grob C., Miller E.N., Ernst T. Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol. Psychiatry 2005, 57:967-974.
30. Chang L., Ernst T., Speck O., Grob C.S. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am. J. Psychiatry 2005, 162:361-369.
31. Chartoff E.H., Szczypka M.S., Palmiter R.D., Dorsa D.M. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy. Brain Res. 2004, 1022:71-80.
32. Cheng W.S., Garfein R.S., Semple S.J., Strathdee S.A., Zians J.K., Patterson T.L. Binge use and sex and drug use behaviors among HIV(-), heterosexual methamphetamine users in San Diego. Subst. Use Misuse 2010, 45:116-133.
33. Cherner M., Suarez P., Casey C., Deiss R., Letendre S., Marcotte T., Vaida F., Atkinson J.H., Grant I., Heaton R.K. Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. Drug Alcohol Depend. 2010, 106:154-163.
34. Chung A., Lyoo I.K., Kim S.J., Hwang J., Bae S.C., Sung Y.H., Sim M.E., Song I.C., Kim J., Chang K.H., Renshaw P.F. Decreased frontal white-matter integrity in abstinent methamphetamine abusers. Int. J. Neuropsychopharmacol. 2007, 10:765-775.
35. Colfax G.N., Santos G.M., Das M., Santos D.M., Matheson T., Gasper J., Shoptaw S., Vittinghoff E. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch. Gen. Psychiatry 2011, 68:1168-1175.
36. Commins D.L., Seiden L.S. Alpha-methyltyrosine blocks methylamphetamine-induced degeneration in the rat somatosensory cortex. Brain Res. 1986, 365:15-20.
37. Cook C.E., Jeffcoat A.R., Perez-Reyes M., Sadler B.M., Hill J.M., White W.R., McDonald S. Plasma levels of methamphetamine after smoking of methamphetamine hydrochloride. NIDA Res. Monogr. 1990, 105:578-579.
38. Cook C.E., Jeffcoat A.R., Sadler B.M., Hill J.M., Voyksner R.D., Pugh D.E., White W.R., Perez-Reyes M. Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. Drug Metab. Dispos. 1992, 20:856-862.
39. Cook C.E., Jeffcoat A.R., Hill J.M., Pugh D.E., Patetta P.K., Sadler B.M., White W.R., Perez-Reyes M. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab. Dispos. 1993, 21:717-723.
40. Cunningham J.K., Maxwell J.C., Campollo O., Cunningham K.I., Liu L.M., Lin H.L. Proximity to the US-Mexico border: a key to explaining geographic variation in US methamphetamine, cocaine and heroin purity. Addiction 2010, 105:1785-1798.
41. Darke S., Kaye S., McKetin R., Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008, 27:253-262.
42. Daumann J., Koester P., Becker B., Wagner D., Imperati D., Gouzoulis-Mayfrank E., Tittgemeyer M. Medial prefrontal gray matter volume reductions in users of amphetamine-type stimulants revealed by combined tract-based spatial statistics and voxel-based morphometry. Neuroimage 2011, 54:794-801.
43. De La Garza R., Zorick T., Heinzerling K.G., Nusinowitz S., London E.D., Shoptaw S., Moody D.E., Newton T.F. The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers. Pharmacol. Biochem. Behav. 2009, 94:186-193.
44. DEA Registration requirements for importers and manufacturers of prescription drug products containing ephedrine, pseudoephedrine, or phenylpropanolamine. Final rule. Fed. Regist. 2010, 75:4973-4982.
45. Di Costanzo A., Trojsi F., Tosetti M., Schirmer T., Lechner S.M., Popolizio T., Scarabino T. Proton MR spectroscopy of the brain at 3T: an update. Eur. Radiol. 2007, 17:1651-1662.
46. Elkashef A.M., Rawson R.A., Anderson A.L., Li S.H., Holmes T., Smith E.V., Chiang N., Kahn R., Vocci F., Ling W., Pearce V.J., McCann M., Campbell J., Gorodetzky C., Haning W., Carlton B., Mawhinney J., Weis D. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008, 33:1162-1170.
47. Ende G.R., Laxer K.D., Knowlton R.C., Matson G.B., Schuff N., Fein G., Weiner M.W. Temporal lobe epilepsy: bilateral hippocampal metabolite changes revealed at proton MR spectroscopic imaging. Radiology 1997, 202:809-817.
48. Ernst T., Chang L., Melchor R., Mehringer C.M. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997, 203:829-836.
49. Ernst T., Chang L., Leonido-Yee M., Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 2000, 54:1344-1349.
50. Farfel G.M., Seiden L.S. Role of hypothermia in the mechanism of protection against serotonergic toxicity, II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J. Pharmacol. Exp. Ther. 1995, 272:868-875.
51. Fasano A., Barra A., Nicosia P., Rinaldi F., Bria P., Bentivoglio A.R., Tonioni F. Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding. Drug Alcohol Depend. 2008, 96:178-182.
52. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., Hanson G.R. New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 2007, 47:681-698.
53. Fleckenstein A.E., Volz T.J., Hanson G.R. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 2009, 56(Suppl. 1):133-138.
54. Floor E., Meng L. Amphetamine releases dopamine from synaptic vesicles by dual mechanisms. Neurosci. Lett. 1996, 215:53-56.
55. Fog J.U., Khoshbouei H., Holy M., Owens W.A., Vaegter C.B., Sen N., Nikandrova Y., Bowton E., McMahon D.G., Colbran R.J., Daws L.C., Sitte H.H., Javitch J.A., Galli A., Gether U. Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 2006, 51:417-429.
56. Frankel P.S., Alburges M.E., Bush L., Hanson G.R., Kish S.J. Brain levels of neuropeptides in human chronic methamphetamine users. Neuropharmacology 2007, 53:447-454.
57. Frankel P.S., Hoonakker A.J., Hanson G.R. Differential response of neurotensin to methamphetamine self-administration. Ann. N. Y. Acad. Sci. 2008, 1139:112-117.
58. Frankel P.S., Hoonakker A.J., Alburges M.E., McDougall J.W., McFadden L.M., Fleckenstein A.E., Hanson G.R. Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia. J. Pharmacol. Exp. Ther. 2011, 336:809-815.
59. Fung Y.K., Uretsky N.J. The differential effects of amphetamine and methylphenidate on the biosynthesis of [3H]dopa from [3H]tyrosine in mouse striata in vivo. J. Pharm. Pharmacol. 1982, 34:531-532.
60. Galloway G.P., Buscemi R., Coyle J.R., Flower K., Siegrist J.D., Fiske L.A., Baggott M.J., Li L., Polcin D., Chen C.Y., Mendelson J. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin. Pharmacol. Ther. 2011, 89:276-282.
61. Glasner-Edwards S., Marinelli-Casey P., Hillhouse M., Ang A., Mooney L.J., Rawson R. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J. Nerv. Ment. Dis. 2009, 197:225-231.
62. Gold M.S., Kobeissy F.H., Wang K.K., Merlo L.J., Bruijnzeel A.W., Krasnova I.N., Cadet J.L. Methamphetamine- and trauma-induced brain injuries: comparative cellular and molecular neurobiological substrates. Biol. Psychiatry 2009, 66:118-127.
63. Gonzales R., Ang A., Marinelli-Casey P., Glik D.C., Iguchi M.Y., Rawson R.A. Health-related quality of life trajectories of methamphetamine-dependent individuals as a function of treatment completion and continued care over a 1-year period. J. Subst. Abuse Treat. 2009, 37:353-361.
64. Gonzalez R., Rippeth J.D., Carey C.L., Heaton R.K., Moore D.J., Schweinsburg B.C., Cherner M., Grant I. Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug Alcohol Depend. 2004, 76:181-190.
65. Graves S.M., Napier T.C. Mirtazapine alters cue-associated methamphetamine seeking in rats. Biol. Psychiatry 2011, 69:275-281.
66. Graves S.M., Napier T.C. SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats. BMC Neurosci. 2012, 13:65.
67. Gross N.B., Duncker P.C., Marshall J.F. Striatal dopamine D1 and D2 receptors: widespread influences on methamphetamine-induced dopamine and serotonin neurotoxicity. Synapse 2011, 65:1144-1155.
68. Gruenewald P.J., Johnson F.W., Ponicki W.R., Remer L.G., Lascala E.A. Assessing correlates of the growth and extent of methamphetamine abuse and dependence in California. Subst. Use Misuse 2010, 45:1948-1970.
69. Hadamitzky M., Markou A., Kuczenski R. Extended access to methamphetamine self-administration affects sensorimotor gating in rats. Behav. Brain Res. 2011, 217:386-390.
70. Halkitis P.N. Methamphetamine Addiction: Biological Foundations, Psychological Factors and Social Consequences 2009, American Psychological Association, Washington, DC.
71. Hamamoto D.T., Rhodus N.L. Methamphetamine abuse and dentistry. Oral Dis. 2009, 15:27-37.
72. Hanson G.R., Bush L., Keefe K.A., Alburges M.E. Distinct responses of basal ganglia substance P systems to low and high doses of methamphetamine. J. Neurochem. 2002, 82:1171-1178.
73. Hanson G.R., Rau K.S., Fleckenstein A.E. The methamphetamine experience: a NIDA partnership. Neuropharmacology 2004, 47(Suppl. 1):92-100.
74. Hanson J.E., Birdsall E., Seferian K.S., Crosby M.A., Keefe K.A., Gibb J.W., Hanson G.R., Fleckenstein A.E. Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment. Eur. J. Pharmacol. 2009, 607:68-73.
75. Hanson G.R., Hoonakker A.J., Alburges M.E., McFadden L.M., Robson C.M., Frankel P.S. Response of limbic neurotensin systems to methamphetamine self-administration. Neuroscience 2012, 203:99-107.
76. Harris D.S., Boxenbaum H., Everhart E.T., Sequeira G., Mendelson J.E., Jones R.E. The bioavailability of intranasal and smoked methamphetamine. Clin. Pharmacol. Ther. 2003, 74:475-485.
77. Harris D.S., Reus V.I., Wolkowitz O.M., Mendelson J.E., Jones R.T. Altering cortisol level does not change the pleasurable effects of methamphetamine in humans. Neuropsychopharmacology 2003, 28:1677-1684.
78. Hart C.L., Ward A.S., Haney M., Foltin R.W., Fischman M.W. Methamphetamine self-administration by humans. Psychopharmacology (Berl.) 2001, 157:75-81.
79. Heinzerling K.G., Shoptaw S., Peck J.A., Yang X., Liu J., Roll J., Ling W. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006, 85:177-184.
80. Heinzerling K.G., Swanson A.N., Kim S., Cederblom L., Moe A., Ling W., Shoptaw S. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2010, 109:20-29.
81. Hogan K.A., Staal R.G., Sonsalla P.K. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J. Neurochem. 2000, 74:2217-2220.
82. Hondebrink L., Meulenbelt J., Timmerman J.G., van den Berg M., Westerink R.H. Amphetamine reduces vesicular dopamine content in dexamethasone-differentiated PC12 cells only following L-DOPA exposure. J. Neurochem. 2009, 111:624-633.
83. Iudicello J.E., Woods S.P., Vigil O., Scott J.C., Cherner M., Heaton R.K., Atkinson J.H., Grant I. Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence. J. Clin. Exp. Neuropsychol. 2010, 32:704-718.
84. Iwanami A., Sugiyama A., Kuroki N., Toda S., Kato N., Nakatani Y., Horita N., Kaneko T. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatr. Scand. 1994, 89:428-432.
85. Iyo M., Namba H., Yanagisawa M., Hirai S., Yui N., Fukui S. Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99MTc-HMPAO and SPECT. Prog. Neuropsychopharmacol. Biol. Psychiatry 1997, 21:789-796.
86. Iyo M., Sekine Y., Mori N. Neuromechanism of developing methamphetamine psychosis: a neuroimaging study. Ann. N. Y. Acad. Sci. 2004, 1025:288-295.
87. Jang C.G., Whitfield T., Schulteis G., Koob G.F., Wee S. A dysphoric-like state during early withdrawal from extended access to methamphetamine self-administration in rats. Psychopharmacology (Berl.) 2012, PMID 23007601 [Epub ahead of print].
88. Johanson C.E., Frey K.A., Lundahl L.H., Keenan P., Lockhart N., Roll J., Galloway G.P., Koeppe R.A., Kilbourn M.R., Robbins T., Schuster C.R. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl.) 2006, 185:327-338.
89. Johnson R.G. Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol. Rev. 1988, 68:232-307.
90. Johnson B.A., Roache J.D., Ait-Daoud N., Wells L.T., Wallace C.L., Dawes M.A., Liu L., Wang X.Q. Effects of acute topiramate dosing on methamphetamine-induced subjective mood. Int. J. Neuropsychopharmacol. 2007, 10:85-98.
91. Johnson B.A., Ait-Daoud N., Elkashef A.M., Smith E.V., Kahn R., Vocci F., Li S.H., Bloch D.A. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int. J. Neuropsychopharmacol. 2008, 11:1-14.
92. Johnston L.D., O'Matlley P.M., Bachman J.G., Schulenberg J.E. Monitoring the Future National Results on Drug Use, 1975-2011 2012, UOMIFS Research, Ann Arbor. http://monitoringthefuture.org/pubs.html.
93. Kahlig K.M., Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur. J. Pharmacol. 2003, 479:153-158.
94. Kahlig K.M., Binda F., Khoshbouei H., Blakely R.D., McMahon D.G., Javitch J.A., Galli A. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3495-3500.
95. Kalechstein A.D., Newton T.F., Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J. Neuropsychiatry Clin. Neurosci. 2003, 15:215-220.
96. Kaushal N., Seminerio M.J., Robson M.J., McCurdy C.R., Matsumoto R.R. Pharmacological evaluation of SN79, a sigma (sigma) receptor ligand, against methamphetamine-induced neurotoxicity in vivo. Eur. Neuropsychopharmacol. 2012, PMID 22921523 [Epub ahead of print].
97. Kerr T., Wood E., Grafstein E., Ishida T., Shannon K., Lai C., Montaner J., Tyndall M.W. High rates of primary care and emergency department use among injection drug users in Vancouver. J. Public Health (Oxf.) 2005, 27:62-66.
98. Kim I.S., Kim Y.T., Song H.J., Lee J.J., Kwon D.H., Lee H.J., Kim M.N., Yoo D.S., Chang Y. Reduced corpus callosum white matter microstructural integrity revealed by diffusion tensor eigenvalues in abstinent methamphetamine addicts. Neurotoxicology 2009, 30:209-213.
99. King G., Alicata D., Cloak C., Chang L. Neuropsychological deficits in adolescent methamphetamine abusers. Psychopharmacology (Berl.) 2010, 212:243-249.
100. King G., Alicata D., Cloak C., Chang L. Psychiatric symptoms and HPA axis function in adolescent methamphetamine users. J. Neuroimmune Pharmacol. 2010, 5:582-591.
101. Kish S.J. Pharmacologic mechanisms of crystal meth. CMAJ 2008, 178:1679-1682.
102. Kiyatkin E.A., Brown P.L., Sharma H.S. Brain edema and breakdown of the blood-brain barrier during methamphetamine intoxication: critical role of brain hyperthermia. Eur. J. Neurosci. 2007, 26:1242-1253.
103. Kobeissy F.H., Mitzelfelt J.D., Fishman I., Morgan D., Gaskins R., Zhang Z., Gold M.S., Wang K.K. Methods in drug abuse models: comparison of different models of methamphetamine paradigms. Methods Mol. Biol. 2012, 829:269-278.
104. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
105. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009, 60:379-407.
106. Krasnova I.N., Justinova Z., Ladenheim B., Jayanthi S., McCoy M.T., Barnes C., Warner J.E., Goldberg S.R., Cadet J.L. Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PLoS ONE 2010, 5:e8790.
107. Kuczenski R., Segal D.S. Differential effects of d- and l-amphetamine and methylphenidate on rat striatal dopamine biosynthesis. Eur. J. Pharmacol. 1975, 30:244-251.
108. Laqueille X., Dervaux A., El Omari F., Kanit M., Bayle F.J. Methylphenidate effective in treating amphetamine abusers with no other psychiatric disorder. Eur. Psychiatry 2005, 20:456-457.
109. Leamon M.H., Flower K., Salo R.E., Nordahl T.E., Kranzler H.R., Galloway G.P. Methamphetamine and paranoia: the methamphetamine experience questionnaire. Am. J. Addict. 2010, 19:155-168.
110. Lecomte T., Mueser K.T., Macewan G.W., Laferriere-Simard M., Thornton A.E., Buchanan T., Goldner E., Brink J., Ehmann T.S., Lang D.J., Kang S., Barr A.M., Honer W.G. Profiles of individuals seeking psychiatric help for psychotic symptoms linked to methamphetamine abuse - baseline results from the MAPS (methamphetamine and psychosis study). Mental Health Subst. Use 2010, 3:168-181.
111. Lee N.K., Rawson R.A. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008, 27:309-317.
112. Lee B., London E.D., Poldrack R.A., Farahi J., Nacca A., Monterosso J.R., Mumford J.A., Bokarius A.V., Dahlbom M., Mukherjee J., Bilder R.M., Brody A.L., Mandelkern M.A. Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J. Neurosci. 2009, 29:14734-14740.
113. Leung J.Y., Barr A.M., Procyshyn R.M., Honer W.G., Pang C.C. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol. Ther. 2012, 135:113-122.
114. Li Y., Cheng S.Y., Chen N., Reith M.E. Interrelation of dopamine transporter oligomerization and surface presence as studied with mutant transporter proteins and amphetamine. J. Neurochem. 2010, 114:873-885.
115. Lile J.A., Stoops W.W., Vansickel A.R., Glaser P.E., Hays L.R., Rush C.R. Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of d-amphetamine in humans. Neuropsychopharmacology 2005, 30:2103-2114.
116. Loftis J.M., Choi D., Hoffman W., Huckans M.S. Methamphetamine causes persistent immune dysregulation: a cross-species, translational report. Neurotox. Res. 2010, 20:59-68.
117. Lominac K.D., Sacramento A.D., Szumlinski K.K., Kippin T.E. Distinct neurochemical adaptations within the nucleus accumbens produced by a history of self-administered vs non-contingently administered intravenous methamphetamine. Neuropsychopharmacology 2012, 37:707-722.
118. London E.D., Simon S.L., Berman S.M., Mandelkern M.A., Lichtman A.M., Bramen J., Shinn A.K., Miotto K., Learn J., Dong Y., Matochik J.A., Kurian V., Newton T., Woods R., Rawson R., Ling W. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch. Gen. Psychiatry 2004, 61:73-84.
119. Longo M., Wickes W., Smout M., Harrison S., Cahill S., White J.M. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction 2010, 105:146-154.
120. Lute B.J., Khoshbouei H., Saunders C., Sen N., Lin R.Z., Javitch J.A., Galli A. PI3K signaling supports amphetamine-induced dopamine efflux. Biochem. Biophys. Res. Commun. 2008, 372:656-661.
121. Mack F., Bonisch H. Dissociation constants and lipophilicity of catecholamines and related compounds. Naunyn-Schmiedeberg's Arch. Pharmacol. 1979, 310:1-9.
122. Mahoney J.J., Jackson B.J., Kalechstein A.D., De la Garza R., Newton T.F. Acute, low-dose methamphetamine administration improves attention/information processing speed and working memory in methamphetamine-dependent individuals displaying poorer cognitive performance at baseline. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:459-465.
123. Mahoney J.J., Jackson B.J., Kalechstein A.D., De La Garza R., Chang L.C., Newton T.F. Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers. Int. J. Neuropsychopharmacol. 2012, 15:1241-1249.
124. Mark K.A., Soghomonian J.J., Yamamoto B.K. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J. Neurosci. 2004, 24:11449-11456.
125. Maxwell J.C., Rutkowski B.A. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. Drug Alcohol Rev. 2008, 27:229-235.
126. McCann U.D., Wong D.F., Yokoi F., Villemagne V., Dannals R.F., Ricaurte G.A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neurosci. 1998, 18:8417-8422.
127. McCann U.D., Kuwabara H., Kumar A., Palermo M., Abbey R., Brasic J., Ye W., Alexander M., Dannals R.F., Wong D.F., Ricaurte G.A. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 2008, 62:91-100.
128. McEwen B.S., Gianaros P.J. Central role of the brain in stress and adaptation: links to socioeconomic status, health, and disease. Ann. N. Y. Acad. Sci. 2010, 1186:190-222.
129. McFadden L.M., Hadlock G.C., Allen S.C., Vieira-Brock P.L., Stout K.A., Ellis J.D., Hoonakker A.J., Andrenyak D.M., Nielsen S.M., Wilkins D.G., Hanson G.R., Fleckenstein A.E. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J. Pharmacol. Exp. Ther. 2012, 340:295-303.
130. McFadden L.M., Hunt M.M., Vieira-Brock P.L., Muehle J., Nielsen S.M., Allen S.C., Hanson G.R., Fleckenstein A.E. Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations. Drug Alcohol Depend. 2012, 126:87-94.
131. McKetin R., Hickey K., Devlin K., Lawrence K. The risk of psychotic symptoms associated with recreational methamphetamine use. Drug Alcohol Rev. 2010, 29:358-363.
132. Mehrjerdi Z.A., Noroozi A., Barr A.M., Ekhtiari H. Attention deficits in chronic methamphetamine users as a potential target for enhancing treatment efficacy. Basic Clin. Neurosci. 2012, 3:5-14.
133. Meijler M.M., Matsushita M., Wirsching P., Janda K.D. Development of immunopharmacotherapy against drugs of abuse. Curr. Drug Discov. Technol. 2004, 1:77-89.
134. Misawa F., Shimizu K., Fujii Y., Miyata R., Koshiishi F., Kobayashi M., Shida H., Oguchi Y., Okumura Y., Ito H., Kayama M., Kashima H. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A cross-sectional study. BMC Psychiatry 2011, 11:118.
135. Misra L., Kofoed L. Risperidone treatment of methamphetamine psychosis. Am. J. Psychiatry 1997, 154:1170.
136. Misra L.K., Kofoed L., Oesterheld J.R., Richards G.A. Olanzapine treatment of methamphetamine psychosis. J. Clin. Psychopharmacol. 2000, 20:393-394.
137. Moszczynska A., Fitzmaurice P., Ang L., Kalasinsky K.S., Schmunk G.A., Peretti F.J., Aiken S.S., Wickham D.J., Kish S.J. Why is parkinsonism not a feature of human methamphetamine users?. Brain 2004, 127:363-370.
138. Narita M., Akai H., Nagumo Y., Sunagawa N., Hasebe K., Nagase H., Kita T., Hara C., Suzuki T. Implications of protein kinase C in the nucleus accumbens in the development of sensitization to methamphetamine in rats. Neuroscience 2004, 127:941-948.
139. Nejtek V.A., Avila M., Chen L.A., Zielinski T., Djokovic M., Podawiltz A., Kaiser K., Bae S., Rush A.J. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. J. Clin. Psychiatry 2008, 69:1257-1266.
140. Newton T.F., Roache J.D., De La Garza R., Fong T., Wallace C.L., Li S.H., Elkashef A., Chiang N., Kahn R. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006, 31:1537-1544.
141. Newton T.F., Reid M.S., De La Garza R., Mahoney J.J., Abad A., Condos R., Palamar J., Halkitis P.N., Mojisak J., Anderson A., Li S.H., Elkashef A. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int. J. Neuropsychopharmacol. 2008, 11:1037-1045.
142. Nordahl T.E., Salo R., Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J. Neuropsychiatry Clin. Neurosci. 2003, 15:317-325.
143. Nordahl T.E., Salo R., Natsuaki Y., Galloway G.P., Waters C., Moore C.D., Kile S., Buonocore M.H. Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Arch. Gen. Psychiatry 2005, 62:444-452.
144. Northrop N.A., Smith L.P., Yamamoto B.K., Eyerman D.J. Regulation of glutamate release by alpha7 nicotinic receptors: differential role in methamphetamine-induced damage to dopaminergic and serotonergic terminals. J. Pharmacol. Exp. Ther. 2011, 336:900-907.
145. Oh J.S., Lyoo I.K., Sung Y.H., Hwang J., Kim J., Chung A., Park K.S., Kim S.J., Renshaw P.F., Song I.C. Shape changes of the corpus callosum in abstinent methamphetamine users. Neurosci. Lett. 2005, 384:76-81.
146. O'Neil M.L., Kuczenski R., Segal D.S., Cho A.K., Lacan G., Melega W.P. Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge. Synapse 2006, 60:465-473.
147. Payer D.E., Lieberman M.D., London E.D. Neural correlates of affect processing and aggression in methamphetamine dependence. Arch. Gen. Psychiatry 2011, 68:271-282.
148. Pontieri F.E., Crane A.M., Seiden L.S., Kleven M.S., Porrino L.J. Metabolic mapping of the effects of intravenous methamphetamine administration in freely moving rats. Psychopharmacology (Berl.) 1990, 102:175-182.
149. Procyshyn R.M., Wasan K.M., Thornton A.E., Barr A.M., Chen E.Y., Pomarol-Clotet E., Stip E., Williams R., Macewan G.W., Birmingham C.L., Honer W.G. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J. Psychiatry Neurosci. 2007, 32:331-338.
150. Procyshyn R.M., Honer W.G., Wu T.K., Ko R.W., McIsaac S.A., Young A.H., Johnson J.L., Barr A.M. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J. Clin. Psychiatry 2010, 71:566-573.
151. Qi J., Yang J.Y., Wang F., Zhao Y.N., Song M., Wu C.F. Effects of oxytocin on methamphetamine-induced conditioned place preference and the possible role of glutamatergic neurotransmission in the medial prefrontal cortex of mice in reinstatement. Neuropharmacology 2009, 56:856-865.
152. Rawson R.A., Anglin M.D., Ling W. Will the methamphetamine problem go away?. J. Addict. Dis. 2002, 21:5-19.
153. Rawson R.A., Marinelli-Casey P., Anglin M.D., Dickow A., Frazier Y., Gallagher C., Galloway G.P., Herrell J., Huber A., McCann M.J., Obert J., Pennell S., Reiber C., Vandersloot D., Zweben J. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 2004, 99:708-717.
154. Reese E.A., Bunzow J.R., Arttamangkul S., Sonders M.S., Grandy D.K. Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J. Pharmacol. Exp. Ther. 2007, 321:178-186.
155. Reichel C.M., Ramsey L.A., Schwendt M., McGinty J.F., See R.E. Methamphetamine-induced changes in the object recognition memory circuit. Neuropharmacology 2012, 62:1119-1126.
156. Revel F.G., Moreau J.L., Gainetdinov R.R., Ferragud A., Velazquez-Sanchez C., Sotnikova T.D., Morairty S.R., Harmeier A., Groebke Zbinden K., Norcross R.D., Bradaia A., Kilduff T.S., Biemans B., Pouzet B., Caron M.G., Canales J.J., Wallace T.L., Wettstein J.G., Hoener M.C. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol. Psychiatry 2012, 72:934-942.
157. Rhodus N.L., Little J.W. Methamphetamine abuse and "meth mouth." PA Dent. J. (Harrisb.) 2008, 75:19-29.
158. Ricaurte G.A., Seiden L.S., Schuster C.R. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res. 1984, 303:359-364.
159. Riddle E.L., Topham M.K., Haycock J.W., Hanson G.R., Fleckenstein A.E. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur. J. Pharmacol. 2002, 449:71-74.
160. Riddle E.L., Fleckenstein A.E., Hanson G.R. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J. 2006, 8:E413-E418.
161. Rippeth J.D., Heaton R.K., Carey C.L., Marcotte T.D., Moore D.J., Gonzalez R., Wolfson T., Grant I. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J. Int. Neuropsychol. Soc. 2004, 10:1-14.
162. Robinson J.B. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl. Biochem. Pharmacol. 1985, 34:4105-4108.
163. Rose M.E., Grant J.E. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann. Clin. Psychiatry 2008, 20:145-155.
164. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., Partilla J.S. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39:32-41.
165. Rusyniak D.E. Neurologic manifestations of chronic methamphetamine abuse. Neurol. Clin. 2011, 29:641-655.
166. Salo R., Nordahl T.E., Possin K., Leamon M., Gibson D.R., Galloway G.P., Flynn N.M., Henik A., Pfefferbaum A., Sullivan E.V. Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Res. 2002, 111:65-74.
167. Salo R., Nordahl T.E., Natsuaki Y., Leamon M.H., Galloway G.P., Waters C., Moore C.D., Buonocore M.H. Attentional control and brain metabolite levels in methamphetamine abusers. Biol. Psychiatry 2007, 61:1272-1280.
168. Salo R., Nordahl T.E., Galloway G.P., Moore C.D., Waters C., Leamon M.H. Drug abstinence and cognitive control in methamphetamine-dependent individuals. J. Subst. Abuse Treat. 2009, 37:292-297.
169. Salo R., Buonocore M.H., Leamon M., Natsuaki Y., Waters C., Moore C.D., Galloway G.P., Nordahl T.E. Extended findings of brain metabolite normalization in MA-dependent subjects across sustained abstinence: a proton MRS study. Drug Alcohol Depend. 2011, 113:133-138.
170. Saunders C., Ferrer J.V., Shi L., Chen J., Merrill G., Lamb M.E., Leeb-Lundberg L.M., Carvelli L., Javitch J.A., Galli A. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6850-6855.
171. Schmitt K.C., Reith M.E. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann. N. Y. Acad. Sci. 2010, 1187:316-340.
172. Schneider F.H. Amphetamine-induced exocytosis of catecholamines from the cow adrenal medulla. J. Pharmacol. Exp. Ther. 1972, 183:80-89.
173. Schuldiner S. A molecular glimpse of vesicular monoamine transporters. J. Neurochem. 1994, 62:2067-2078.
174. Schwartz K., Weizman A., Rehavi M. The effect of psychostimulants on [3H]dopamine uptake and release in rat brain synaptic vesicles. J. Neural Transm. 2006, 113:1347-1352.
175. Scott J.C., Woods S.P., Matt G.E., Meyer R.A., Heaton R.K., Atkinson J.H., Grant I. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol. Rev. 2007, 17:275-297.
176. Segal D.S., Kuczenski R. Escalating dose-binge stimulant exposure: relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens dopamine responses. Psychopharmacology (Berl.) 1999, 142:182-192.
177. Segal D.S., Kuczenski R. Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. Neuropsychopharmacology 2006, 31:941-955.
178. Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., Yoshikawa E., Futatsubashi M., Takei N., Mori N. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am. J. Psychiatry 2001, 158:1206-1214.
179. Sekine Y., Minabe Y., Kawai M., Suzuki K., Iyo M., Isoda H., Sakahara H., Ashby C.R., Takei N., Mori N. Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study. Neuropsychopharmacology 2002, 27:453-461.
180. Sekine Y., Ouchi Y., Takei N., Yoshikawa E., Nakamura K., Futatsubashi M., Okada H., Minabe Y., Suzuki K., Iwata Y., Tsuchiya K.J., Tsukada H., Iyo M., Mori N. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch. Gen. Psychiatry 2006, 63:90-100.
181. Shearer J., Wodak A., Mattick R.P., Van Beek I., Lewis J., Hall W., Dolan K. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 2001, 96:1289-1296.
182. Shoblock J.R., Sullivan E.B., Maisonneuve I.M., Glick S.D. Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology (Berl.) 2003, 165:359-369.
183. Shoptaw S., Heinzerling K.G., Rotheram-Fuller E., Steward T., Wang J., Swanson A.N., De La Garza R., Newton T., Ling W. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2008, 96:222-232.
184. Simon S.L., Domier C., Carnell J., Brethen P., Rawson R., Ling W. Cognitive impairment in individuals currently using methamphetamine. Am. J. Addict. 2000, 9:222-231.
185. Smith K.E., Walker M.W., Artymyshyn R., Bard J., Borowsky B., Tamm J.A., Yao W.J., Vaysse P.J., Branchek T.A., Gerald C., Jones K.A. Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J. Biol. Chem. 1998, 273:23321-23326.
186. Stoops W.W., Lile J.A., Glaser P.E., Rush C.R. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend. 2006, 84:206-209.
187. Sulzer D., Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 1990, 5:797-808.
188. Sulzer D., Maidment N.T., Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem. 1993, 60:527-535.
189. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 2005, 75:406-433.
190. Talloczy Z., Martinez J., Joset D., Ray Y., Gacser A., Toussi S., Mizushima N., Nosanchuk J., Goldstein H., Loike J., Sulzer D., Santambrogio L. Methamphetamine inhibits antigen processing, presentation, and phagocytosis. PLoS Pathog. 2008, 4:e28.
191. Tata D.A., Raudensky J., Yamamoto B.K. Augmentation of methamphetamine-induced toxicity in the rat striatum by unpredictable stress: contribution of enhanced hyperthermia. Eur. J. Neurosci. 2007, 26:739-748.
192. Tedeschi G., Bertolino A., Lundbom N., Bonavita S., Patronas N.J., Duyn J.H., Metman L.V., Chase T.N., Di Chiro G. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology 1996, 47:696-704.
193. Thompson P.M., Hayashi K.M., Simon S.L., Geaga J.A., Hong M.S., Sui Y., Lee J.Y., Toga A.W., Ling W., London E.D. Structural abnormalities in the brains of human subjects who use methamphetamine. J. Neurosci. 2004, 24:6028-6036.
194. Tiihonen J., Kuoppasalmi K., Fohr J., Tuomola P., Kuikanmaki O., Vorma H., Sokero P., Haukka J., Meririnne E. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am. J. Psychiatry 2007, 164:160-162.
195. Tobias M.C., O'Neill J., Hudkins M., Bartzokis G., Dean A.C., London E.D. White-matter abnormalities in brain during early abstinence from methamphetamine abuse. Psychopharmacology (Berl.) 2010, 209:13-24.
196. Tong J., Ross B.M., Schmunk G.A., Peretti F.J., Kalasinsky K.S., Furukawa Y., Ang L.C., Aiken S.S., Wickham D.J., Kish S.J. Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users. Am. J. Psychiatry 2003, 160:896-903.
197. Tsukada H., Nishiyama S., Kakiuchi T., Ohba H., Sato K., Harada N. Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride?: PET studies combined with microdialysis in conscious monkeys. Brain Res. 1999, 841:160-169.
198. Tulloch I., Afanador L., Mexhitaj I., Ghazaryan N., Garzagongora A.G., Angulo J.A. A single high dose of methamphetamine induces apoptotic and necrotic striatal cell loss lasting up to 3 months in mice. Neuroscience 2011, 193:162-169.
199. United Nations Office on Drugs and Crime World Drug Report, 2008. United Nations Publication Sales No. E08XI1. http://www.unodc.org/unodc/en/data-and-analysis/WDR-2008.html.
200. van der Plas E.A., Crone E.A., van den Wildenberg W.P., Tranel D., Bechara A. Executive control deficits in substance-dependent individuals: a comparison of alcohol, cocaine, and methamphetamine and of men and women. J. Clin. Exp. Neuropsychol. 2009, 31:706-719.
201. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M., Gatley S.J., Miller E., Hitzemann R., Ding Y.S., Logan J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 2001, 21:9414-9418.
202. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Wong C., Logan J. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am. J. Psychiatry 2001, 158:383-389.
203. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Logan J., Wong C., Miller E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 2001, 158:377-382.
204. Wachtel S.R., Ortengren A., de Wit H. The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend. 2002, 68:23-33.
205. Wang G.J., Volkow N.D., Chang L., Miller E., Sedler M., Hitzemann R., Zhu W., Logan J., Ma Y., Fowler J.S. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am. J. Psychiatry 2004, 161:242-248.
206. Weiland-Fiedler P., Erickson K., Waldeck T., Luckenbaugh D.A., Pike D., Bonne O., Charney D.S., Neumeister A. Evidence for continuing neuropsychological impairments in depression. J. Affect. Disord. 2004, 82:253-258.
207. Werb D., Kerr T., Zhang R., Montaner J.S., Wood E. Methamphetamine use and malnutrition among street-involved youth. Harm Reduct. J. 2010, 7:5.
208. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996, 2:699-703.
209. Woods S.P., Rippeth J.D., Conover E., Gongvatana A., Gonzalez R., Carey C.L., Cherner M., Heaton R.K., Grant I. Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence. Neuropsychology 2005, 19:35-43.
210. Xie Z., Miller G.M. A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain. J. Pharmacol. Exp. Ther. 2009, 330:316-325.
211. Zorick T., Nestor L., Miotto K., Sugar C., Hellemann G., Scanlon G., Rawson R., London E.D. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 2010, 105:1809-1818.